Höcht Christian, Di Verniero Carla, Opezzo Javier A W, Taira Carlos A
Cátedra de Farmacología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD, Argentina.
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):1-8. doi: 10.1007/s00210-004-0945-2. Epub 2004 Jul 22.
The present study addressed possible alterations in the pharmacodynamic and pharmacokinetic properties of the beta1-adrenoceptor antagonist metoprolol in experimental hypertension induced by abdominal aortic coarctation (ACo). Metoprolol's pharmacokinetics and its relationship with its in vivo chronotropic and blood pressure effect were studied using the microdialysis technique. A pharmacokinetic-pharmacodynamic model with a separate effect compartment was used to analyse the data. No differences were found in the calculated pharmacokinetic parameters between sham-operated (SO) and ACo rats. Bradycardia was observed after the i.v. injection of metoprolol (3 or 10 mg/kg) without differences between the experimental groups. The decrease of mean arterial pressure (DeltaMAP) induced by metoprolol was greater in ACo than in SO rats: SO: -14+/-2 mmHg, n=5; ACo: -26+/-4 mmHg, n=5, P<0.05. The dissociation constant (expressed as pKb) of metoprolol and its inverse agonistic activity were studied in isolated atria. The pKb of metoprolol was similar in both groups of animals (SO: 7.49+/-0.20; ACo: 7.19+/-0.23). The inverse agonistic activity of metoprolol on spontaneous beating of isolated atria was established by means of a concentration/response curve. There were no differences in maximum response (Emax; SO: -28+/-2.0%, n=5; ACo: -27+/-4%, n=5) or the concentration eliciting a half-maximal effect (pEC50) (SO: 4.9+/-0.2, n=5; ACo: 5.2+/-0.2, n=5) between the experimental groups. These results suggest that chronic ACo does not modify the beta-adrenoceptor affinity of metoprolol or its inverse agonistic activity. Moreover, there was no difference in the in vivo chronotropic effect between the experimental groups, indicating the absence of cardiac sympathetic over-activity in this model of hypertension. The pharmacokinetic results suggest that the metabolism of metoprolol is not affected in chronic ACo rats. In addition, the greater sensitivity to the depressor effect of metoprolol in ACo rats in the chronic hypertensive stage suggests a participation of the beta-adrenoceptors in the maintenance of hypertension.
本研究探讨了β1肾上腺素能受体拮抗剂美托洛尔在腹主动脉缩窄(ACo)诱导的实验性高血压中,其药效学和药代动力学特性可能发生的改变。采用微透析技术研究了美托洛尔的药代动力学及其与体内变时性和血压效应的关系。使用具有独立效应室的药代动力学-药效学模型分析数据。在假手术(SO)大鼠和ACo大鼠之间,计算得到的药代动力学参数未发现差异。静脉注射美托洛尔(3或10mg/kg)后观察到心动过缓,各实验组之间无差异。美托洛尔诱导的平均动脉压降低(ΔMAP)在ACo大鼠中比在SO大鼠中更大:SO:-14±2mmHg,n = 5;ACo:-26±4mmHg,n = 5,P<0.05。在离体心房中研究了美托洛尔的解离常数(以pKb表示)及其反向激动活性。两组动物中美托洛尔的pKb相似(SO:7.49±0.20;ACo:7.19±0.23)。通过浓度/反应曲线确定了美托洛尔对离体心房自发搏动的反向激动活性。各实验组之间在最大反应(Emax;SO:-28±2.0%,n = 5;ACo:-27±4%,n = 5)或引起半数最大效应的浓度(pEC50)(SO:4.9±0.2,n = 5;ACo:5.2±0.2,n = 5)方面没有差异。这些结果表明,慢性ACo不会改变美托洛尔的β肾上腺素能受体亲和力或其反向激动活性。此外,各实验组之间在体内变时性效应方面没有差异,表明在该高血压模型中不存在心脏交感神经过度活动。药代动力学结果表明,慢性ACo大鼠中美托洛尔的代谢不受影响。此外,在慢性高血压阶段,ACo大鼠对美托洛尔降压作用的敏感性更高,提示β肾上腺素能受体参与了高血压的维持。